Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12456 |
PI3K-IN-10
|
PI3K | PI3K/Akt/mTOR signaling |
PI3K-IN-10 is a potent inhibitor of pan-PI3K . | |||
T62013 |
PI3Kδ-IN-10
|
||
PI3Kδ-IN-10 是高效的、具有口服活性的PI3Kδ抑制剂(IC50= 2 nM)。在肝细胞癌模型中,PI3Kδ-IN-10 强烈抑制下游AKT 通路,并诱导细胞凋亡(apoptosis)。 | |||
T64219 |
PI3K/mTOR Inhibitor-6
|
||
PI3K/mTOR Inhibitor-6 (Compound 19c) 是一种有效的 PI3K/mTOR 双重抑制剂,在人工胃液中的稳定性比 gedatolisib 更高。10 μM 的 PI3K/mTOR Inhibitor-6 能够明显抑制 PI3K/Akt/mTOR 信号通路。PI3K/mTOR Inhibitor-6 对癌症疾病表现出研究潜力。 | |||
T62409 | PI3K-IN-23 | ||
PI3K-IN-23 是一种 (E)-9-oxooctadec-10-en-12-ynoic acid 类似物,能够促进葡萄糖摄取 (EC50: 7.00 μM)。 | |||
T64041 | PI3K/mTOR Inhibitor-7 | ||
PI3K/mTOR Inhibitor-7 是有效的 PI3K/mTOR 双重抑制剂。PI3K/mTOR Inhibitor-7 的作用比 gedatolisib 高 4.7 倍,他们的 IC50 值分别为 1.4 μM 和 0.3 μM。10 μM 的 PI3K/mTOR Inhibitor-7 能够明显抑制 PI3K/Akt/mTOR 信号通路。PI3K/mTOR Inhibitor-7 对癌症疾病表现出研究潜力。 | |||
T63211 | AKT-IN-10 | ||
AKT-IN-10 是有效的 AKT 抑制剂,对乳腺癌和前列腺癌表现出研究潜力。其中蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。 | |||
T36421 | Immuno-Oncology Screening Library | ||
The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list ... | |||
T79449 |
Antileishmanial agent-19
|
Parasite | Microbiology/Virology |
Antileishmanial agent-19 (Compound F27)是一种有效的抗利什曼病试剂,其对L. donovani promastigotes的IC50值为3.39 μM。该化合物能够抑制L. donovani promastigotes中的脯氨酰-tRNA合成酶,并干预宿主PI3K/Akt/CREB轴,从而抑制IL-10的分泌。此外,Antileishmanial agent-19能诱导L. donovani promastigotes自噬介导的细胞凋亡(apoptosis)过程,并在感染的动物体内显著减少寄生虫负担。 | |||
T78871 |
PLM-101
|
||
PLM-101是一种口服抗癌剂,针对FLT3和RET具有选择性抑制作用,有效抑制急性髓系白血病(AML)细胞。通过抑制RET,PLM-101促使FLT3的自噬降解,并且通过抑制PI3K和Ras/ERK信号通路来发挥其抗白血病的活性。在小鼠MV4-11侧翼异种移植模型中,PLM-101以口服剂量3及10 mg/kg显示出抗肿瘤效果,并且在同种异种移植小鼠模型中,剂量为40 mg/kg(口服)亦展现出明显的抗肿瘤功效。 | |||
T36308 |
PF-06843195
|
||
PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy[1]. PF-06843195 inhibits the breast cancer cell lines MCF7 and T47D proliferation with IC50s of 62 nM and 32 nM, respectively[1].PF-06843195 inhibits pAKT (T308) in MCF7 and T47D cells w... |